Novartis AG (VIE:NOVN)
Austria · Delayed Price · Currency is EUR | Market Cap | 235.77B +27.0% |
| Revenue (ttm) | 48.27B +9.6% |
| Net Income | 11.91B +17.1% |
| EPS | 6.09 +21.8% |
| Shares Out | n/a |
| PE Ratio | 19.80 |
| Forward PE | 16.51 |
| Dividend | 4.10 (3.32%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | n/a |
| Average Volume | 3 |
| Open | 124.72 |
| Previous Close | 126.42 |
| Day's Range | 124.72 - 124.90 |
| 52-Week Range | 94.21 - 143.52 |
| Beta | n/a |
| RSI | 29.79 |
| Earnings Date | Apr 28, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a...
Novartis Receives European Commission Approval For Rhapsido In Chronic Spontaneous Urticaria
(RTTNews) - Novartis (NVS) announced on Monday that the European Commission has approved Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with an inadequate response t...
Novartis receives European Commission approval for Rhapsido skin disease drug
Novartis has received European Commission approval for its drug Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU), the Swiss drugmaker said on Monday.
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Basel, April 27, 2026 – Novartis announced today that the European Commission (EC) approved Rhapsido® (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response ...
Novartis Pulls EMA Filing For New Pluvicto Use After CHMP Pushback
(RTTNews) - Novartis (NVS) has withdrawn its European Medical Agency (EMA) application seeking to expand the use of Pluvicto in prostate cancer, after regulators signaled, they would not support the s...
Novartis' Itvisma Moves Closer To EU Approval With Positive CHMP Opinion
(RTTNews) - Novartis (NVS) has received a positive opinion from the European Medicines Agency's CHMP for Itvisma, bringing the one-time gene replacement therapy a step closer to approval for older chi...
Novartis (NVS) Receives Positive CHMP Opinion for Itvisma Authorization
Novartis (NVS) Receives Positive CHMP Opinion for Itvisma Authorization
Novartis (NVS) Achieves WHO Prequalification for Coartem Baby
Novartis (NVS) Achieves WHO Prequalification for Coartem Baby
Novartis (NVS) Achieves WHO Prequalification for Coartem Baby Antimalarial
Novartis (NVS) Achieves WHO Prequalification for Coartem Baby Antimalarial
Novartis Secures WHO Nod For Infant Malaria Therapy Coartem Baby
(RTTNews) - Novartis (NVS) has announced that the World Health Organization (WHO) has prequalified Coartem Baby, the first and only malaria treatment developed specifically for newborns and young infa...
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Basel, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifical...
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
East Hanover, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed spe...
Changemakers Spotlight: Novartis EVP Reshema Kemps-Polanco
Novartis US EVP and Chief Commercial Officer Reshema Kemps-Polanco shares how the passing of a close friend gives her work purpose.
Better Pharma Dividend Stock: Novartis vs. Merck
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
Govt seeks Novartis response, eyes generics to fix thalassemia drug shortage
Govt to seek Novartis response on thalassemia iron chelation drug tender gaps, explore generic production and CSR support to ease shortages in hospitals.
Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs
BOSTON--(BUSINESS WIRE)--Instem announces the appointment of Szczepan Baran, VMD, MS, as Chief Scientific Officer to lead Instem's scientific and AI strategy.
Big Pharma Deepens AI Ties. What It Means For Novo, Novartis.
Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday.
Anthropic Expands Board with Novartis CEO Amid IPO Plans
Anthropic Expands Board with Novartis CEO Amid IPO Plans
Novartis Partners with OpenAI to Enhance AI Integration in Pharma
Novartis Partners with OpenAI to Enhance AI Integration in Pharma
Anthropic Adds Novartis CEO to Board
The startup behind the popular Claude chatbot and coding tool is eyeing a potential IPO as soon as this year.
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Basel, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as publ...
PPH, NVS, SNY, NVO: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the VanEck Pharmaceutical ETF (Symbol: PPH) where we have detected an appr...
Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy
Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy
Novartis: Fabhalta Cut Kidney Function Decline By 49.3% In IgAN
(RTTNews) - Novartis (NVS) reported final two-year results from its Phase 3 APPLAUSE IgAN study, showing that Fabhalta (iptacopan) slowed the decline in kidney function by 49.3% compared with placebo....
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically...